- Home
- INTS vs EQ Comparison
INTS vs EQ Comparison
Compare INTS & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- EQ
- Stock Information
- Founded
- INTS 2012
- EQ 2017
- Country
- INTS United States
- EQ United States
- Employees
- INTS N/A
- EQ N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- INTS Health Care
- EQ Health Care
- Exchange
- INTS Nasdaq
- EQ Nasdaq
- Market Cap
- INTS 33.4M
- EQ 31.1M
- IPO Year
- INTS 2023
- EQ 2018
- Fundamental
- Price
- INTS $2.23
- EQ $0.88
- Analyst Decision
- INTS Strong Buy
- EQ Buy
- Analyst Count
- INTS 3
- EQ 2
- Target Price
- INTS $8.50
- EQ $5.00
- AVG Volume (30 Days)
- INTS 26.6K
- EQ 2.2M
- Earning Date
- INTS 03-13-2025
- EQ 03-24-2025
- Dividend Yield
- INTS N/A
- EQ N/A
- EPS Growth
- INTS N/A
- EQ N/A
- EPS
- INTS N/A
- EQ N/A
- Revenue
- INTS N/A
- EQ $45,914,000.00
- Revenue This Year
- INTS N/A
- EQ $4.77
- Revenue Next Year
- INTS N/A
- EQ N/A
- P/E Ratio
- INTS N/A
- EQ N/A
- Revenue Growth
- INTS N/A
- EQ 7.70
- 52 Week Low
- INTS $1.50
- EQ $0.49
- 52 Week High
- INTS $5.94
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- INTS 49.26
- EQ 58.42
- Support Level
- INTS $1.84
- EQ $0.85
- Resistance Level
- INTS $2.27
- EQ $0.98
- Average True Range (ATR)
- INTS 0.28
- EQ 0.10
- MACD
- INTS -0.01
- EQ 0.01
- Stochastic Oscillator
- INTS 56.36
- EQ 62.50
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.